| 常用名 | 依诺苏单抗 | CAS号 | 1192578-27-0 |
|---|---|---|---|
| 价格 | ¥需询单/1g ¥需询单/5g | 纯度 | 98.0% |
| 备货期 | 需询单 | 库存 | 现货 |
| 产品详情(用途,包装等)
用途: Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively[1]. 物理化学性质: CAS号:1192578-27-0 常用中文名:依诺苏单抗 常用英文名:Enoticumab 分子式: 分子量: 密度:N/A 沸点:N/A 熔点:N/A 闪点:N/A |